Product Details
| Model | XIENCE PRO A |
| Brand | ABBOTT |
| Category | Stents |
| Posted | 12.02.2026 |
| Views | 3804 |
ABBOTT LABS ABBOTT XIENCE PRO A STENT SYSTEM Stent
Condition:: New
Availability:: In stock
Shipping from:: 
Poland
PolandSeller:
trustproapproved
Poland
Certmed is an experienced supplier of medical devices. For years, we have been supporting our clients in sourcing medical products quickly and at competitive prices. We offer trusted, well-known products from leading market players.<br/><br/>Our expertise spans a wide range of fields, including Cardiology, Nephrology, Intensive Care, Surgery, Urology, Neurology, and many more.<br/><br/>We encourage you to get in touch with us directly.
Description
The XIENCE PRO Everolimus Eluting Coronary Stent System is indicated for improving
coronary luminal diameter in the following:
- Patients with symptomatic ischemic heart disease due to discrete
de novo
native
coronary artery lesions.
- For restoring coronary flow in patients experiencing acute myocardial infarction who
present within 12 hours of symptom onset.
- For the treatment of patients with concomitant diabetes, acute coronary syndr
ome,
dual vessel lesions (two lesions in two different epicardial vessels), lesions residing
within small coronary vessels; lesions where treatment results in the jailing of side
branches (lesions with a side branch < 2 mm in diameter or an ostial stenosis
< 50%); for the treatment of elderly patients (age ≥ 65), and for treatment of both
men and women.
- For the treatment of patients presenting with in-stent restenosis in coronary artery
lesions; chr
onic total occluded coronary artery lesions (defined as coronary artery
lesions with TIMI flow 0 and lasting longer than 3 months); and coronary artery
bifurcation lesions.
Transport from Warsaw within 7 days. Please contact for more details.
coronary luminal diameter in the following:
- Patients with symptomatic ischemic heart disease due to discrete
de novo
native
coronary artery lesions.
- For restoring coronary flow in patients experiencing acute myocardial infarction who
present within 12 hours of symptom onset.
- For the treatment of patients with concomitant diabetes, acute coronary syndr
ome,
dual vessel lesions (two lesions in two different epicardial vessels), lesions residing
within small coronary vessels; lesions where treatment results in the jailing of side
branches (lesions with a side branch < 2 mm in diameter or an ostial stenosis
< 50%); for the treatment of elderly patients (age ≥ 65), and for treatment of both
men and women.
- For the treatment of patients presenting with in-stent restenosis in coronary artery
lesions; chr
onic total occluded coronary artery lesions (defined as coronary artery
lesions with TIMI flow 0 and lasting longer than 3 months); and coronary artery
bifurcation lesions.
Transport from Warsaw within 7 days. Please contact for more details.
Didn’t find what you were looking for? Place your own ad on the Bimedis platform
Place your advert on Bimedis and reach buyers worldwide.